Repurposing metabolic drugs as anti-inflammatory agents
Recent evidence from clinical use is highlighting the anti-inflammatory properties of two classes of metabolic drugs, glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter 2 (SGLT2) inhibitors.
The molecular underpinnings of the anti-inflammatory actions of these medications are emerging and suggest improvements in systemic metabolism paired with direct anti-inflammatory mechanisms, but large gaps in our understanding remain.
Understanding the mechanisms underlying the anti-inflammatory effects may reveal potential therapeutic opportunities outside of metabolic diseases.
https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(25)00149-3
